Project Grant R21CA296465
Award Date 6/1/26
Completion Date 5/31/28
Dollars Obligated $458K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Irwindale, CA 91010, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Beckman Research Institute of the City of Hope a $702,495 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2030. This research initiative focuses on developing novel therapeutic approaches to treat T cell lymphomas (TCLs), a highly heterogeneous group of lymphoid malignancies representing approximately 12% of all non-Hodgkin lymphomas. The project...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the Beckman Research Institute of the City of Hope a $517,090 Project Grant under the Cancer Biology Research program (CFDA 93.396) on August 18, 2025, to investigate the role and biological function of a novel signature gene designated AL021978.1 (A978) in Philadelphia chromosome (PH)-positive and PH-like B-cell acute lymphoblastic leukemia (B-ALL). The research aims to address high-risk leukemia subtypes with survival...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $694,015 Project Grant to Beckman Research Institute of the City of Hope under the Cancer Biology Research program (CFDA 93.396) for the period July 1, 2026 through June 30, 2031. This five-year award funds research to identify and target cancer immune evasion signals that allow tumor cells to evade macrophage-mediated surveillance and elimination. The project focuses on characterizing phagocytosis...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Feinstein Institutes for Medical Research a $167,500 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This research initiative addresses chronic lymphocytic leukemia (CLL), the most prevalent adult leukemia in the United States, by investigating the cellular and molecular mechanisms underlying communication between cancer cells and...
- Federal Grant Award Summary H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $1,098,920 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective August 13, 2025, with completion targeted for April 30, 2030. The research focuses on understanding the transcriptional and epigenetic control of CD8+ tumor-infiltrating lymphocytes (TILs) and tumor memory cells to enhance anti-tumor immune responses....
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $483,395 Project Grant under the Cancer Treatment Research program (CFDA 93.395) beginning September 1, 2025, and concluding August 31, 2027. This research initiative focuses on investigating P300 and CBP (Cyclic AMP-Response Element Binding Protein) as novel therapeutic targets in renal cell carcinoma (RCC), specifically clear cell RCC (ccRCC). The project will examine the therapeutic potential...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $650,597 Project Grant to the University of California, San Diego under the Cancer Treatment Research program (CFDA 93.395) for the period April 1, 2026 through March 31, 2031. This research project investigates the role of B-cells in durable complete responses to checkpoint blockade immunotherapy (CBI) in head and neck squamous cell carcinoma (HNSCC). While response rates to CBI in HNSCC remain generally low,...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Grant Award Summary The National Cancer Institute (NCI) awarded a $733,864 Project Grant to the Beckman Research Institute of the City of Hope under the Cancer Biology Research program (CFDA 93.396) for a five-year research initiative spanning June 1, 2026 through May 31, 2031. The research focuses on identifying and characterizing a novel stimulatory immune checkpoint that regulates macrophage-mediated programmed cell removal (PRCR), a critical process in tumor surveillance and immune response....
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $235,491 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) awarded May 1, 2026, with completion targeted for April 30, 2031. This award supports biomedical research training and career development in cancer research aligned with the National Cancer Program's strategic priorities. The research initiative focuses on investigating the biology and phenotypic...